Tolerance to Electrostimulation in COPD Patients (TOES)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00809120|
Recruitment Status : Completed
First Posted : December 17, 2008
Last Update Posted : June 10, 2010
The study was designed to test the following hypothesis
Patients with high cardio-respiratory response to electrostimulation (ES), high perception of pain during ES and high ES-induced muscle fatigue, have low tolerance to ES (more difficulties to increase intensity during training).
|Condition or disease||Intervention/treatment||Phase|
|COPD||Device: Neuromuscular Electrical stimulator (Cefar rehab 4 pro)||Not Applicable|
Background: Muscle electrostimulation (ES) appears as a promising alternative to general physical reconditioning in advanced COPD and its feasibility has been confirmed in this population. However, patients are not equal in tolerance to ES. Certain patients are not able to increase ES intensity during training, limiting its benefits. Furthermore, little is known about the effect of one ES training session on cardio-respiratory response, muscle fatigue and systemic inflammation in COPD patients.
Objective: To evaluate the tolerance to ES in COPD patients and to identify the physiological parameters involved in ES tolerance.
Method: We propose to conduct a prospective study including 21 COPD patients of different pulmonary severity (7 in each group of GOLD II, III and IV). Patients will be evaluated 3 times: at day 1, day 2 and day 9. In the first session, patients will be initiated to ES and evaluated in walking distance. In the second session, patients will become autonomous with ES and they will be evaluated in muscle strength and body composition. In the third session, cardio-respiratory measurements will be performed during ES and patients will be evaluated in muscle strength and systemic inflammation (blood sampling) before and after ES. Between the 2d and the 3d sessions, patients will have to perform 5 ES sessions at home (from day 3 to day 8). Tolerance (symptoms assessed with visual analogical scale (VAS)) and intensity of ES will be measured during each ES session.
Planning analysis: The main outcome will be the change in ES intensity between session 2 and 3 (delta intensity). The other end-points will be minute ventilation, heart rate, VO2 and SaO2 during ES, but also change in ES tolerance (VAS) during ES at equal ES intensity, leg muscle fatigue after ES, body composition and changes in plasmatic proteins after ES. Simple and multiple regressions analysis will be done between delta intensity and 1/cardio-respiratory response during ES, 2/muscle fatigue after ES, 3/body composition, 4/perception of pain at session 2 (VAS), 5/changes in plasmatic proteins after ES.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Investigation of Clinical Tolerance, Cardio-respiratory Response and Muscle Fatigue During Electrostimulation|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||August 2009|
Device: Neuromuscular Electrical stimulator (Cefar rehab 4 pro)
- Tolerance to ES = Change in ES intensity between session 2 and 3 (delta intensity) [ Time Frame: 1 week ]
- Cardiorespiratory response during ES [ Time Frame: 1 week ]
- Muscle fatigue after ES [ Time Frame: 1 week ]
- Body composition [ Time Frame: 1 week ]
- Perception of pain at session 2 (symptoms on Visual Analogic Scale) [ Time Frame: 1 week ]
- Plasmatic proteins after ES [ Time Frame: 1 week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00809120
|Quebec City, Quebec, Canada, G1V4G5|